{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T04:18:46Z","timestamp":1791778726124,"version":"4.3.4"},"reference-count":66,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["FOC"],"published-print":{"date-parts":[[2011,5]]},"abstract":"<jats:sec>\n                    <jats:title>Object<\/jats:title>\n                    <jats:p>The standard surgical treatment for meningiomas is total resection, but the complete removal of skull base meningiomas can be difficult for several reasons. Thus, the management of certain meningiomas of the skull base\u2014for example, those involving basal vessels and cranial nerves\u2014remains a challenge. In recent reports it has been suggested that somatostatin (SST) administration can cause growth inhibition of unresectable and recurrent meningiomas. The application of SST and its analogs is not routinely integrated into standard treatment strategies for meningiomas, and clinical studies proving growth-inhibiting effects do not exist. The authors report on their experience using octreotide in patients with recurrent or unresectable meningiomas of the skull base.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Between January 1996 and December 2010, 13 patients harboring a progressive residual meningioma (as indicated by MR imaging criteria) following operative therapy were treated with a monthly injection of the SST analog octreotide (Sandostatin LAR [long-acting repeatable] 30 mg, Novartis). Eight of 13 patients had a meningioma of the skull base and were analyzed in the present study. Postoperative tumor enlargement was documented in all patients on MR images obtained before the initiation of SST therapy. All tumors were benign. No patient received radiation or chemotherapy before treatment with SST. The growth of residual tumor was monitored by MR imaging every 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Three of the 8 patients had undergone surgical treatment once; 3, 2 times; and 2, 3 times. The mean time after the last meningioma operation (before starting SST treatment) and tumor enlargement as indicated by MR imaging criteria was 24 months. A total of 643 monthly cycles of Sandostatin LAR were administered. Five of the 8 patients were on SST continuously and stabilized disease was documented on MR images obtained in these patients during treatment (median 115 months, range 48\u2013180 months). Three of the 8 patients interrupted treatment: after 60 months in 1 case because of tumor progression, after 36 months in 1 case because of side effects, and after 36 months in 1 case because the health insurance company denied cost absorption.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although no case of tumor regression was detected on MR imaging, the study results indicated that SST analogs can arrest the progression of unresectable or recurrent benign meningiomas of the skull base in some patients. It remains to be determined whether a controlled prospective clinical trial would be useful.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3171\/2011.1.focus111","type":"journal-article","created":{"date-parts":[[2016,12,27]],"date-time":"2016-12-27T10:40:44Z","timestamp":1482835244000},"page":"E11","source":"Crossref","is-referenced-by-count":37,"title":["Treatment of unresectable skull base meningiomas with somatostatin analogs"],"prefix":"10.3171","volume":"30","author":[{"given":"Chris","family":"Schulz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe Max","family":"Mauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"key":"b1-0300011","series-title":"Acta Neurochir (Wien)","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s007010070108","article-title":"Gamma knife radiosurgery of skull base meningiomas","volume":"142","author":"Aichholzer","year":"2000"},{"key":"b2-0300011","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1023\/B:NEON.0000013498.19981.55","article-title":"Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity","volume":"66","author":"Arena","year":"2004"},{"key":"b3-0300011","series-title":"Neurology","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1212\/01.wnl.0000271382.62776.b7","article-title":"Recurrent meningioma: salvage therapy with long-acting somatostatin analogue","volume":"69","author":"Chamberlain","year":"2007"},{"key":"b4-0300011","series-title":"Front Biosci (Elite Ed)","first-page":"494","article-title":"Nonsurgical treatment options in the management of intracranial meningiomas","volume":"1","author":"Dashti","year":"2009"},{"key":"b5-0300011","series-title":"J Endocrinol Invest","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/BF03345185","article-title":"Development of a meningioma in a patient with acromegaly during octreotide treatment: are there any causal relationships?","volume":"26","author":"De Menis","year":"2003"},{"key":"b6-0300011","series-title":"Int J Cancer","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/(SICI)1097-0215(19980529)76:5<620::AID-IJC2>3.0.CO;2-S","article-title":"Expression of somatostatin receptor subtypes in human brain tumors","volume":"76","author":"Dutour","year":"1998"},{"key":"b7-0300011","series-title":"J Neurosurg Sci","first-page":"237","article-title":"Clinical use of octreotide in unresectable meningiomas. A report of three cases","volume":"37","author":"Garc\u00eda-Luna","year":"1993"},{"key":"b8-0300011","series-title":"Stereotact Funct Neurosurg","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1159\/000321184","article-title":"Gamma knife robotic microradiosurgery for benign skull base meningiomas: tumor shrinkage may depend on the amount of radiation energy delivered per lesion volume (unit energy)","volume":"89","author":"Hayashi","year":"2011"},{"key":"b9-0300011","series-title":"Acta Neurochir (Wien)","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/BF01476412","article-title":"High sensitivity of the in vivo detection of somatostatin receptors by 111indium (DTPA-octreotide)-scintigraphy in meningioma patients","volume":"126","author":"Hildebrandt","year":"1994"},{"key":"b10-0300011","series-title":"Clin Neurol Neurosurg","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0303-8467(97)00110-8","article-title":"Visual improvement during octreotide therapy in a case of episellar meningioma","volume":"100","author":"Jaffrain-Rea","year":"1998"},{"key":"b11-0300011","series-title":"Skull Base","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1055\/s-2007-1003925","article-title":"Molecular biology of unreresectable meningiomas: implications for new treatments and review of the literature","volume":"18","author":"Jagannathan","year":"2008"},{"key":"b12-0300011","series-title":"Neurosurgery","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1097\/00006123-200003000-00008","article-title":"Long-term outcome and growth rate of subtotally resected petroclival meningiomas: experience with 38 cases","volume":"46","author":"Jung","year":"2000"},{"key":"b13-0300011","series-title":"J Clin Endocrinol Metab","first-page":"543","article-title":"Somatostatin inhibits the activity of adenylate cyclase in cultured human meningioma cells and stimulates their growth","volume":"74","author":"Koper","year":"1992"},{"key":"b14-0300011","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3171\/jns.1985.62.1.0018","article-title":"Meningioma: analysis of recurrence and progression following neurosurgical resection","volume":"62","author":"Mirimanoff","year":"1985"},{"issue":"4","key":"b15-0300011","series-title":"Neurosurg Focus","doi-asserted-by":"publisher","first-page":"E11","DOI":"10.3171\/FOC-07\/10\/E11","article-title":"Hydroxyurea chemotherapy in the treatment of meningiomas","volume":"23","author":"Newton","year":"2007"},{"key":"b16-0300011","series-title":"Neurosurgery","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1227\/01.NEU.0000068730.76856.58","article-title":"The natural history of incidental meningiomas","volume":"53","author":"Nakamura","year":"2003"},{"key":"b17-0300011","series-title":"Zentralbl Neurochir","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1055\/s-2004-836225","article-title":"Volumetric analysis of the growth rate of incompletely resected intracranial meningiomas","volume":"66","author":"Nakamura","year":"2005"},{"key":"b18-0300011","series-title":"Proc Natl Acad Sci U S A","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1073\/pnas.042705099","article-title":"Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells","volume":"99","author":"Patel","year":"2002"},{"key":"b19-0300011","series-title":"Front Neuroendocrinol","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1006\/frne.1999.0183","article-title":"Somatostatin and its receptor family","volume":"20","author":"Patel","year":"1999"},{"key":"b20-0300011","series-title":"Trends Endocrinol Metab","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/S1043-2760(97)00168-9","article-title":"Somatostatin receptors","volume":"8","author":"Patel","year":"1997"},{"key":"b21-0300011","series-title":"Tumori","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1177\/030089160308900206","article-title":"The role of somatostatin in vasogenic meningioma associated brain edema","volume":"89","author":"Pistolesi","year":"2003"},{"key":"b22-0300011","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009"},{"key":"b23-0300011","series-title":"Science","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1126\/science.288.5463.154","article-title":"Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity","volume":"288","author":"Rocheville","year":"2000"},{"key":"b24-0300011","series-title":"J Biol Chem","doi-asserted-by":"publisher","first-page":"7862","DOI":"10.1074\/jbc.275.11.7862","article-title":"Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers","volume":"275","author":"Rocheville","year":"2000"},{"issue":"4","key":"b25-0300011","series-title":"Neurosurg Focus","first-page":"E1","article-title":"Intracranial meningiomas: an overview of diagnosis and treatment","volume":"23","author":"Rockhill","year":"2007"},{"key":"b26-0300011","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/S0140-6736(89)92465-3","article-title":"Successful treatment of meningioma with octreotide","volume":"333","author":"R\u00fcnzi","year":"1989"},{"key":"b27-0300011","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0140-6736(89)90400-5","article-title":"Treatment of meningioma with octreotide","volume":"334","author":"R\u00fcnzi","year":"1989"},{"key":"b28-0300011","series-title":"Mol Cell Endocrinol","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.mce.2007.09.006","article-title":"Pasireotide (SOM230): development, mechanism of action and potential applications","volume":"286","author":"Schmid","year":"2008"},{"key":"b29-0300011","series-title":"Neurosurgery","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1227\/NEU.0b013e3181fb801b","article-title":"Vascular endothelial growth factor: the major factor for tumor neovascularization and edema formation in meningioma patients","volume":"67","author":"Schmid","year":"2010"},{"key":"b30-0300011","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-008-9734-y","article-title":"Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas","volume":"92","author":"Sioka","year":"2009"},{"key":"b31-0300011","series-title":"Scand J Gastroenterol Suppl","first-page":"136","article-title":"Somatostatin octapeptide (SMS 201-995) in the medical treatment of acromegaly","volume":"119","author":"Wass","year":"1986"},{"key":"b32-0300011","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s11060-010-0349-8","article-title":"Medical therapies for meningiomas","volume":"99","author":"Wen","year":"2010"},{"key":"b33-0300011","series-title":"J Neurol","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00415-008-0801-2","article-title":"Growth rate of non-operated meningiomas","volume":"255","author":"Zeidman","year":"2008"},{"key":"b1-0300011","series-title":"Acta Neurochir (Wien)","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s007010070108","article-title":"Gamma knife radiosurgery of skull base meningiomas","volume":"142","author":"Aichholzer","year":"2000"},{"key":"b2-0300011","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1023\/B:NEON.0000013498.19981.55","article-title":"Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity","volume":"66","author":"Arena","year":"2004"},{"key":"b3-0300011","series-title":"Neurology","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1212\/01.wnl.0000271382.62776.b7","article-title":"Recurrent meningioma: salvage therapy with long-acting somatostatin analogue","volume":"69","author":"Chamberlain","year":"2007"},{"key":"b4-0300011","series-title":"Front Biosci (Elite Ed)","first-page":"494","article-title":"Nonsurgical treatment options in the management of intracranial meningiomas","volume":"1","author":"Dashti","year":"2009"},{"key":"b5-0300011","series-title":"J Endocrinol Invest","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/BF03345185","article-title":"Development of a meningioma in a patient with acromegaly during octreotide treatment: are there any causal relationships?","volume":"26","author":"De Menis","year":"2003"},{"key":"b6-0300011","series-title":"Int J Cancer","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/(SICI)1097-0215(19980529)76:5<620::AID-IJC2>3.0.CO;2-S","article-title":"Expression of somatostatin receptor subtypes in human brain tumors","volume":"76","author":"Dutour","year":"1998"},{"key":"b7-0300011","series-title":"J Neurosurg Sci","first-page":"237","article-title":"Clinical use of octreotide in unresectable meningiomas. A report of three cases","volume":"37","author":"Garc\u00eda-Luna","year":"1993"},{"key":"b8-0300011","series-title":"Stereotact Funct Neurosurg","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1159\/000321184","article-title":"Gamma knife robotic microradiosurgery for benign skull base meningiomas: tumor shrinkage may depend on the amount of radiation energy delivered per lesion volume (unit energy)","volume":"89","author":"Hayashi","year":"2011"},{"key":"b9-0300011","series-title":"Acta Neurochir (Wien)","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/BF01476412","article-title":"High sensitivity of the in vivo detection of somatostatin receptors by 111indium (DTPA-octreotide)-scintigraphy in meningioma patients","volume":"126","author":"Hildebrandt","year":"1994"},{"key":"b10-0300011","series-title":"Clin Neurol Neurosurg","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0303-8467(97)00110-8","article-title":"Visual improvement during octreotide therapy in a case of episellar meningioma","volume":"100","author":"Jaffrain-Rea","year":"1998"},{"key":"b11-0300011","series-title":"Skull Base","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1055\/s-2007-1003925","article-title":"Molecular biology of unreresectable meningiomas: implications for new treatments and review of the literature","volume":"18","author":"Jagannathan","year":"2008"},{"key":"b12-0300011","series-title":"Neurosurgery","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1097\/00006123-200003000-00008","article-title":"Long-term outcome and growth rate of subtotally resected petroclival meningiomas: experience with 38 cases","volume":"46","author":"Jung","year":"2000"},{"key":"b13-0300011","series-title":"J Clin Endocrinol Metab","first-page":"543","article-title":"Somatostatin inhibits the activity of adenylate cyclase in cultured human meningioma cells and stimulates their growth","volume":"74","author":"Koper","year":"1992"},{"key":"b14-0300011","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3171\/jns.1985.62.1.0018","article-title":"Meningioma: analysis of recurrence and progression following neurosurgical resection","volume":"62","author":"Mirimanoff","year":"1985"},{"issue":"4","key":"b15-0300011","series-title":"Neurosurg Focus","doi-asserted-by":"publisher","first-page":"E11","DOI":"10.3171\/FOC-07\/10\/E11","article-title":"Hydroxyurea chemotherapy in the treatment of meningiomas","volume":"23","author":"Newton","year":"2007"},{"key":"b16-0300011","series-title":"Neurosurgery","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1227\/01.NEU.0000068730.76856.58","article-title":"The natural history of incidental meningiomas","volume":"53","author":"Nakamura","year":"2003"},{"key":"b17-0300011","series-title":"Zentralbl Neurochir","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1055\/s-2004-836225","article-title":"Volumetric analysis of the growth rate of incompletely resected intracranial meningiomas","volume":"66","author":"Nakamura","year":"2005"},{"key":"b18-0300011","series-title":"Proc Natl Acad Sci U S A","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1073\/pnas.042705099","article-title":"Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells","volume":"99","author":"Patel","year":"2002"},{"key":"b19-0300011","series-title":"Front Neuroendocrinol","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1006\/frne.1999.0183","article-title":"Somatostatin and its receptor family","volume":"20","author":"Patel","year":"1999"},{"key":"b20-0300011","series-title":"Trends Endocrinol Metab","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/S1043-2760(97)00168-9","article-title":"Somatostatin receptors","volume":"8","author":"Patel","year":"1997"},{"key":"b21-0300011","series-title":"Tumori","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1177\/030089160308900206","article-title":"The role of somatostatin in vasogenic meningioma associated brain edema","volume":"89","author":"Pistolesi","year":"2003"},{"key":"b22-0300011","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009"},{"key":"b23-0300011","series-title":"Science","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1126\/science.288.5463.154","article-title":"Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity","volume":"288","author":"Rocheville","year":"2000"},{"key":"b24-0300011","series-title":"J Biol Chem","doi-asserted-by":"publisher","first-page":"7862","DOI":"10.1074\/jbc.275.11.7862","article-title":"Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers","volume":"275","author":"Rocheville","year":"2000"},{"issue":"4","key":"b25-0300011","series-title":"Neurosurg Focus","first-page":"E1","article-title":"Intracranial meningiomas: an overview of diagnosis and treatment","volume":"23","author":"Rockhill","year":"2007"},{"key":"b26-0300011","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/S0140-6736(89)92465-3","article-title":"Successful treatment of meningioma with octreotide","volume":"333","author":"R\u00fcnzi","year":"1989"},{"key":"b27-0300011","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0140-6736(89)90400-5","article-title":"Treatment of meningioma with octreotide","volume":"334","author":"R\u00fcnzi","year":"1989"},{"key":"b28-0300011","series-title":"Mol Cell Endocrinol","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.mce.2007.09.006","article-title":"Pasireotide (SOM230): development, mechanism of action and potential applications","volume":"286","author":"Schmid","year":"2008"},{"key":"b29-0300011","series-title":"Neurosurgery","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1227\/NEU.0b013e3181fb801b","article-title":"Vascular endothelial growth factor: the major factor for tumor neovascularization and edema formation in meningioma patients","volume":"67","author":"Schmid","year":"2010"},{"key":"b30-0300011","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-008-9734-y","article-title":"Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas","volume":"92","author":"Sioka","year":"2009"},{"key":"b31-0300011","series-title":"Scand J Gastroenterol Suppl","first-page":"136","article-title":"Somatostatin octapeptide (SMS 201-995) in the medical treatment of acromegaly","volume":"119","author":"Wass","year":"1986"},{"key":"b32-0300011","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s11060-010-0349-8","article-title":"Medical therapies for meningiomas","volume":"99","author":"Wen","year":"2010"},{"key":"b33-0300011","series-title":"J Neurol","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00415-008-0801-2","article-title":"Growth rate of non-operated meningiomas","volume":"255","author":"Zeidman","year":"2008"}],"container-title":["Neurosurgical Focus"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/neurosurg-focus\/30\/5\/2011.1.focus111.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/neurosurg-focus\/30\/5\/2011.1.focus111.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/neurosurg-focus\/30\/5\/2011.1.focus111.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T08:47:16Z","timestamp":1780130836000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/neurosurg-focus\/30\/5\/2011.1.focus111.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":66,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.3171\/2011.1.focus111","relation":{},"ISSN":["1092-0684"],"issn-type":[{"value":"1092-0684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}